Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Gieschke

Showing results (11-20 of 21) with videos related to

Pageof 3
Sort By:
Clinical Pharmacology and Therapeutics|May 20, 1998
Pharmacokinetic and pharmacodynamic interactions between fluoxetine and moclobemide in the investigation of development of the "serotonin syndrome"J Dingemanse, A Wallnöfer, R Gieschke, et al.
Journal of Pharmacokinetics and Pharmacodynamics|August 27, 2002
Population pharmacokinetic analysis of the major metabolites of capecitabineR Gieschke, B Reigner, K S Blesch, et al.
CPT: Pharmacometrics & Systems Pharmacology|October 4, 2013
Modeling Alzheimer's Disease Progression Using Disease Onset Time and Disease Trajectory Concepts Applied to CDR-SOB Scores From ADNII Delor, J-E Charoin, R Gieschke, et al.
Methods and Findings in Experimental and Clinical Pharmacology|November 1, 1994
Effects of bretazenil vs. zolpidem and placebo on experimentally induced sleep disturbance in healthy volunteersR Gieschke, R Cluydts, J Dingemanse, et al.
International Journal of Clinical Pharmacology and Therapeutics|December 28, 2006
Population pharmacokinetics of ibandronate in Caucasian and Japanese healthy males and postmenopausal femalesG Pillai, R Gieschke, T Goggin, et al.
Journal of Pharmacokinetics and Pharmacodynamics|October 20, 2006
Modelling response time profiles in the absence of drug concentrations: definition and performance evaluation of the K-PD modelP Jacqmin, E Snoeck, E A van Schaick, et al.
Journal of Clinical Pharmacology|August 1, 1995
Pharmacokinetics and pharmacodynamics of Ro 41-3696, a novel nonbenzodiazepine hypnoticJ Dingemanse, M Bury, G Roncari, et al.
Clinical Pharmacology and Therapeutics|May 1, 1995
Integrated pharmacokinetics and pharmacodynamics of the novel catechol-O-methyltransferase inhibitor tolcapone during first administration to humansJ Dingemanse, K M Jorga, M Schmitt, et al.
Journal of Psychopharmacology (Oxford, England)|December 14, 2011
Potentiation of the pressor effect of oral and intravenous tyramine during administration of the selective MAO-A inhibitor moclobemide in healthy volunteersS Wijnands, P C Chang, G J Blauw, et al.
Psychopharmacology|January 1, 1993
Pharmacodynamic interactions of diazepam and intravenous alcohol at pseudo steady stateA L van Steveninck, R Gieschke, H C Schoemaker, et al.
Pageof 3

Showing results (11-20 of 21) with videos related to

Sort By:
Pageof 3
Clinical Pharmacology and Therapeutics|May 20, 1998
Pharmacokinetic and pharmacodynamic interactions between fluoxetine and moclobemide in the investigation of development of the "serotonin syndrome"J Dingemanse, A Wallnöfer, R Gieschke, et al.
Journal of Pharmacokinetics and Pharmacodynamics|August 27, 2002
Population pharmacokinetic analysis of the major metabolites of capecitabineR Gieschke, B Reigner, K S Blesch, et al.
CPT: Pharmacometrics & Systems Pharmacology|October 4, 2013
Modeling Alzheimer's Disease Progression Using Disease Onset Time and Disease Trajectory Concepts Applied to CDR-SOB Scores From ADNII Delor, J-E Charoin, R Gieschke, et al.
Methods and Findings in Experimental and Clinical Pharmacology|November 1, 1994
Effects of bretazenil vs. zolpidem and placebo on experimentally induced sleep disturbance in healthy volunteersR Gieschke, R Cluydts, J Dingemanse, et al.
International Journal of Clinical Pharmacology and Therapeutics|December 28, 2006
Population pharmacokinetics of ibandronate in Caucasian and Japanese healthy males and postmenopausal femalesG Pillai, R Gieschke, T Goggin, et al.
Journal of Pharmacokinetics and Pharmacodynamics|October 20, 2006
Modelling response time profiles in the absence of drug concentrations: definition and performance evaluation of the K-PD modelP Jacqmin, E Snoeck, E A van Schaick, et al.
Journal of Clinical Pharmacology|August 1, 1995
Pharmacokinetics and pharmacodynamics of Ro 41-3696, a novel nonbenzodiazepine hypnoticJ Dingemanse, M Bury, G Roncari, et al.
Clinical Pharmacology and Therapeutics|May 1, 1995
Integrated pharmacokinetics and pharmacodynamics of the novel catechol-O-methyltransferase inhibitor tolcapone during first administration to humansJ Dingemanse, K M Jorga, M Schmitt, et al.
Journal of Psychopharmacology (Oxford, England)|December 14, 2011
Potentiation of the pressor effect of oral and intravenous tyramine during administration of the selective MAO-A inhibitor moclobemide in healthy volunteersS Wijnands, P C Chang, G J Blauw, et al.
Psychopharmacology|January 1, 1993
Pharmacodynamic interactions of diazepam and intravenous alcohol at pseudo steady stateA L van Steveninck, R Gieschke, H C Schoemaker, et al.
Pageof 3